This function is exclusive for Premium subscribers

  • DATABASE (45)

  • ARTICLES (22)

    • DATABASE (45)
    • ARTICLES (22)

Founded in 2016, Shanjin Capital is a PE fund manager approved by the Asset Management Association of China. With a focus on new energy and emerging technologies, the firm mainly invests in clean energy, connected vehicles, medtech and healthcare.

Leaguer Venture Capital was founded by Leaguer Group in 1999 as a wholly-owned subsidiary, responsible for incubating and investing in high-tech startups. It mainly invests in early- and mid-stage tech startups. 

Beijing Zhongguancun Development Qihang Industrial Investment Fund was launched by Zhongguancun Development Group, a hi-tech commercialization platform backed by the municipal government of Beijing. It focuses on biotechnology, pharmaceuticals, next-generation information technology, new energy, new materials and intelligent manufacturing. 

Founded in 2009, Septwolves Venture Capital is a subsidiary of Septwolves Holding Group Co Ltd. The VC firm currently manages assets worth RMB 1bn.Focusing on investment opportunities in the communications and other traditional industries like logistics, Septwolves also invests in diverse sectors including mobile internet, energy, food, pharmaceutical, textile and software.

Founded in 2018, Trinity Innovation Fund is a fund management firm that mainly invests in pharmaceutical innovations. TIF currently manages two PE funds and its limited partners include renowned pharmaceuticals and institutional investors. It also has offices managing funds overseas, for example, Trinity Innovation Bioventure Singapore Pte Ltd.

Founded by Hillhouse Capital in February 2020, GL Ventures mainly invests in early-stage startups from diverse sectors like pharmaceutical, SaaS, internet-based consumption/technology and emerging consumer goods/services.The RMB/USD dual currency VC-arm of Hillhouse currently manages total funds worth RMB 10bn from limited partners including university endowments, sovereign wealth funds, pension funds, FOF and family offices. The VC has made nearly 200 investments in its first year of operations.

Beyond Investing is a Geneva-based firm investing in early-stage venture capital and equity growth startups mainly in European developed markets. With average investments of €200,000, the firm’s core investment strategy focuses on sustainability with an investment period lasting 5–10 years.The impact investor targets innovative startups involved in vegan, cruelty-free and plant-based alternatives; biotechnologies, foodtech, new materials, clothing and lifestyle sectors. Successful portfolio foodtechs include Mosa Meat, BlueNalu and Shiok Meats.With a team of vegan finance professionals in the US and Europe, Beyond Investing listed the first US Vegan Climate ETF (VEGN) on the New York Stock Exchange in September 2019. The ETF tracks Beyond Investing’s US Vegan Climate Index which covers an index of 495 of the largest-capitalization companies in the US stock market. The ethical investment option aims to exclude stocks in companies with activities that are not aligned with its vegan-themed, cruelty-free and fossil-fuel-free investing ethos.

Focused on life sciences, OrbiMed has been investing in the global healthcare industry for over 20 years. Its portfolio ranges from early-stage startups to multinational corporations. With more than 100 scientific, medical, and investment professionals, it manages over $17bn assets worldwide.

Yingke PE was founded in 2010 and is headquartered in Shanghai. By the end of 2020, it had managed assets worth nearly RMB 50bn. In May 2021, it closed the RMB 10bn Yingke Science & Technology Innovation Industrial Fund. Over 90% of its funds come from financial institutions, state-owned enterprises and listed companies. Yingke PE has invested in more than 200 companies, focusing on biopharmaceuticals, core technology and upgraded consumption. Since its founding, the company has exited 53 projects, with an internal rate of return up to 54%.

Xora Innovation is a subsidiary of the Singapore sovereign investment fund, Temasek. It was established as an early-stage deeptech investment platform that identifies startups connected with the Singapore science and technology ecosystem (although the startup can be based anywhere in the world). Xora plans to invest as a lead or co-lead in seed or Series A rounds, with later-stage investments being handled through Temasek. As of July 2021, Xora has invested in two companies based in Singapore: Allozymes, which provides enzyme engineering services, and Nuevocor, which is developing gene therapy for certain heart diseases.

UBS is a Switzerland-based financial institution providing banking, wealth management, and securities services. Originally established in 1862 as the Bank in Winterthur, it is the largest Swiss banking institution. UBS engages in venture capital activities as part of its investment banking services. In 2020, UBS began a partnership with venture capital firm Anthemis to launch UBS Next, a $200m fund that will invest in fintech and other tech startups.

Founded in Hong Kong in 2018, Lake Bleu Capital currently operates in both Hong Kong and Shanghai. With assets worth billions of US dollars under management, it mainly invests in pharmaceuticals, biotech, medical devices and healthcare services companies in Asia, especially Greater China. Its limited partners include sovereign wealth funds, university endowments, foundations, pension funds, and family offices across the world.With a long-term investment strategy, Lake Bleu Capital invests through both public and private equity with a focus on mid- to late-stage companies.

Founded in 2017, Suzhou Longmen Ventures mainly invests in businesses working on innovative drugs and medical devices. It manages tens of billions RMB in assets. 

Founded in 2018, Linden Asset Group currently has offices in Nanjing, Shenzhen and Singapore. With both US dollar- and RMB-denominated funds under management, it is focused on the fields of biotechnology, medtech and smart technology in the Asia Pacific region. Linden Asset prefers growth-stage startups that are cutting-edge in their respective areas and plans for overseas expansion.

Bristol Myers Squibb or BMS is one of the world’s largest biopharmaceutical companies developing medicines in oncology, hematology, immunology and cardiovascular disease. It invests directly and via VC funds, including Life Sciences Partners (LSP) and BioGeneration Ventures, as LP. BMS is headquartered in New York and has 10 offices and facilities within the US and 13 in overseas locations, namely, Puerto Rico, Canada, France, Belgium, the UK, Ireland, Germany, Japan and China. 

Your payment was not successful.

Please make sure you have entered your payment details correctly. Or try again in a few moments.

small logo

The discount code you entered is invalid

Please make sure you have entered your discount code correctly. Or try again in a few moments.

Download successful.

Your sample has been sent. Please check your email.

By accessing and using and all pages within the domain (the “Website”), You accept and agree to have read, understood, accepted and agreed to be bound by the Terms of Use and Privacy Policy in full. If you disagree with all or any part of these Terms of Use and Privacy Policy, please do not use or continue any further use of this website. You acknowledge that you are aware that this Website contains an archive of existing content as at 31 December 2021 and is not being actively managed. We are under no obligation to update the content on this Website and, accordingly, no new content or articles will be posted to the Website after 31 December 2021.